• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2005 年至 2018 年西班牙房颤相关缺血性卒中的流行病学及其与 DOAC 使用率的关系:首个全国性基于人群的研究。

Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018.

机构信息

Servicio de Neurología, Hospital Universitario 12 de Octubre, Madrid, Spain.

Servicio de Cardiología, Complex Hospitalari Moisès Broggi, Sant Joan Despí, Barcelona, Spain.

出版信息

Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):496-505. doi: 10.1016/j.rec.2021.07.009. Epub 2021 Sep 10.

DOI:10.1016/j.rec.2021.07.009
PMID:34518112
Abstract

INTRODUCTION AND OBJECTIVES

The incidence and prevalence of atrial fibrillation (AF), a major risk factor for stroke, has increased substantially in the past few years. However, several studies have reported a decline in AF-related stroke rates associated with higher uptake of direct oral anticoagulants (DOACs). This ecological study evaluated the association between DOAC uptake in Spain and the incidence rate (IR) of AF-related ischemic stroke.

METHODS

Data were obtained from the Registry of Activity of Specialized Healthcare of the Spanish Ministry of Health (RAE-MDS). AF-related ischemic strokes were identified using International Classification of Diseases codes. IR were age-standardized and adjusted to the 2013 European standard population. Poisson regression models were used to identify the association between DOAC uptake and AF-related ischemic stroke in patients aged ≥ 65 years.

RESULTS

Before the use of DOACs, the adjusted IR of AF-related ischemic stroke increased steadily from 2005 (IR=2.20 per 100 000 person/y) to 2012 (IR=2.67). Upon DOAC uptake in Spain from 2012 onwards for AF-related ischemic stroke prevention, the IR remained constant or decreased slightly (IR in 2018=2.66). Poisson regression showed that DOAC uptake was a significant predictor for the rate of AF-related ischemic stroke in patients older than 65 years (IRR=0.995; 95%CI, 0.995-0.996).

CONCLUSIONS

This study shows an association between DOAC use and a reduced incidence of AF-related ischemic stroke. While this association is based on aggregate data and cannot demonstrate causality, these findings suggest that higher DOAC uptake could improve health outcomes in AF patients in Spain.

摘要

引言和目的

心房颤动(AF)是中风的主要危险因素,其发病率和患病率在过去几年中大幅上升。然而,一些研究报告称,随着直接口服抗凝剂(DOAC)的应用增加,AF 相关中风的发生率有所下降。本生态研究评估了西班牙 DOAC 使用率与 AF 相关缺血性中风发生率之间的关联。

方法

数据来自西班牙卫生部专业医疗保健活动登记处(RAE-MDS)。使用国际疾病分类代码识别 AF 相关缺血性中风。将年龄标准化并调整为 2013 年欧洲标准人口。使用泊松回归模型确定≥65 岁患者中 DOAC 使用率与 AF 相关缺血性中风之间的关联。

结果

在使用 DOAC 之前,AF 相关缺血性中风的调整后发病率从 2005 年(发病率为每 100000 人/年 2.20)稳步上升到 2012 年(发病率为每 100000 人/年 2.67)。自 2012 年西班牙开始使用 DOAC 预防 AF 相关缺血性中风以来,发病率保持不变或略有下降(2018 年发病率为 2.66)。泊松回归显示,DOAC 使用率是>65 岁患者 AF 相关缺血性中风发生率的一个显著预测因素(IRR=0.995;95%CI,0.995-0.996)。

结论

本研究表明 DOAC 使用与 AF 相关缺血性中风发生率降低之间存在关联。虽然这种关联基于汇总数据,不能证明因果关系,但这些发现表明,西班牙 AF 患者中 DOAC 使用率的提高可能改善其健康结果。

相似文献

1
Epidemiology of atrial fibrillation-related ischemic stroke and its association with DOAC uptake in Spain: first national population-based study 2005 to 2018.2005 年至 2018 年西班牙房颤相关缺血性卒中的流行病学及其与 DOAC 使用率的关系:首个全国性基于人群的研究。
Rev Esp Cardiol (Engl Ed). 2022 Jun;75(6):496-505. doi: 10.1016/j.rec.2021.07.009. Epub 2021 Sep 10.
2
Direct oral anticoagulants versus vitamin K antagonists in real-world patients with nonvalvular atrial fibrillation. The FANTASIIA study.真实世界中非瓣膜性心房颤动患者使用直接口服抗凝剂与维生素K拮抗剂的比较。FANTASIIA研究。
Rev Esp Cardiol (Engl Ed). 2020 Jan;73(1):14-20. doi: 10.1016/j.rec.2019.02.021. Epub 2019 May 31.
3
Evidence of the association between increased use of direct oral anticoagulants and a reduction in the rate of atrial fibrillation-related stroke and major bleeding at the population level (2012-2019).人群水平上直接口服抗凝剂使用增加与房颤相关卒中及大出血发生率降低的相关性证据(2012-2019 年)。
Med Clin (Barc). 2024 Mar 8;162(5):220-227. doi: 10.1016/j.medcli.2023.10.008. Epub 2023 Nov 20.
4
[Current situation of direct oral anticoagulants in primary care in Spain: Positioning of SEMERGEN in 2023].[西班牙基层医疗中直接口服抗凝剂的现状:2023年西班牙初级保健医生协会(SEMERGEN)的立场]
Semergen. 2024 Apr;50(3):102136. doi: 10.1016/j.semerg.2023.102136. Epub 2023 Dec 5.
5
Uptake in antithrombotic treatment and its association with stroke incidence in atrial fibrillation: insights from a large German claims database.抗血栓治疗的应用及其与心房颤动患者中风发生率的相关性:来自德国大型索赔数据库的研究结果。
Clin Res Cardiol. 2019 Sep;108(9):1042-1052. doi: 10.1007/s00392-019-01437-7. Epub 2019 Feb 15.
6
DOAC versus VKA in patients with atrial fibrillation and bioprosthetic valves: a systematic review and meta-analysis.直接口服抗凝药与维生素 K 拮抗剂在合并生物瓣的心房颤动患者中的应用:一项系统评价和荟萃分析。
Rev Esp Cardiol (Engl Ed). 2023 Sep;76(9):690-699. doi: 10.1016/j.rec.2023.02.002. Epub 2023 Feb 17.
7
Trends in Oral Anticoagulant Use Among 436 864 Patients With Atrial Fibrillation in Community Practice, 2011 to 2020.2011 年至 2020 年社区实践中 436864 例房颤患者口服抗凝剂使用趋势。
J Am Heart Assoc. 2022 Nov 15;11(22):e026723. doi: 10.1161/JAHA.122.026723. Epub 2022 Nov 8.
8
Prescription Patterns and Outcomes of Patients With Atrial Fibrillation Treated With Direct Oral Anticoagulants and Warfarin: A Real-World Analysis.直接口服抗凝剂和华法林治疗心房颤动患者的处方模式和结局:真实世界分析。
J Cardiovasc Pharmacol Ther. 2019 Sep;24(5):428-434. doi: 10.1177/1074248419841634. Epub 2019 Apr 29.
9
[Novel oral anticoagulants in non-valvular atrial fibrillation: How to improve its management in Spain].
Semergen. 2019 Mar;45(2):109-116. doi: 10.1016/j.semerg.2018.10.008. Epub 2018 Dec 21.
10
Influence of Direct Oral Anticoagulants on Rates of Oral Anticoagulation for Atrial Fibrillation.直接口服抗凝药对房颤患者口服抗凝治疗率的影响。
J Am Coll Cardiol. 2017 May 23;69(20):2475-2484. doi: 10.1016/j.jacc.2017.03.540.

引用本文的文献

1
Practical Comprehensive Approach to Current Atrial Fibrillation Challenges: Insights from an Expert Panel.应对当前房颤挑战的实用综合方法:专家小组见解
J Clin Med. 2025 Jul 22;14(15):5199. doi: 10.3390/jcm14155199.
2
Framing anticoagulation control according to clinical practice for patients with atrial fibrillation in Spain: a multidisciplinary vision trough AMFA Project.根据西班牙心房颤动患者的临床实践制定抗凝控制方案:通过AMFA项目的多学科视角
Front Cardiovasc Med. 2025 Mar 5;12:1426072. doi: 10.3389/fcvm.2025.1426072. eCollection 2025.
3
Prevalence of atrial fibrillation in ischemic stroke and associated risk factors: A hospital-based study in Indonesia.
缺血性卒中中心房颤动的患病率及相关危险因素:印度尼西亚一项基于医院的研究。
Brain Circ. 2024 Dec 28;10(4):316-323. doi: 10.4103/bc.bc_36_24. eCollection 2024 Oct-Dec.
4
No disadvantages for women in acute stroke care in Germany: an analysis of access to stroke treatment services in Germany from 2017 to 2022.德国急性中风护理中女性不存在劣势:对2017年至2022年德国中风治疗服务可及性的分析
Neurol Res Pract. 2025 Feb 20;7(1):8. doi: 10.1186/s42466-025-00365-4.
5
Clinical Outcome and Costs Based on the Degree of Vitamin K Antagonist Control for Non-Valvular Atrial Fibrillation.基于非瓣膜性心房颤动维生素K拮抗剂控制程度的临床结局和成本
J Clin Med. 2025 Feb 4;14(3):998. doi: 10.3390/jcm14030998.
6
Left atrial appendage orifice morphology in sickness and in health.疾病状态与健康状态下的左心耳口形态
Herz. 2025 Jun;50(3):185-191. doi: 10.1007/s00059-024-05277-8. Epub 2024 Oct 16.
7
Severity, Outcomes, and their Secular Changes in 33,870 Ischemic Stroke Patients with Atrial Fibrillation in a Hospital-Based Registry: Japan Stroke Data Bank.基于医院登记的33870例合并心房颤动的缺血性卒中患者的严重程度、结局及其长期变化:日本卒中数据库
J Atheroscler Thromb. 2025 Mar 1;32(3):308-320. doi: 10.5551/jat.65117. Epub 2024 Aug 29.
8
Novel Anticoagulants for Stroke Prevention in Atrial Fibrillation: A Comprehensive Review.用于心房颤动卒中预防的新型抗凝剂:综述
Cureus. 2024 Jul 25;16(7):e65347. doi: 10.7759/cureus.65347. eCollection 2024 Jul.
9
Atrial Fibrillation and Reperfusion Therapy in Acute Ischaemic Stroke Patients: Prevalence and Outcomes-A Comprehensive Systematic Review and Meta-Analysis.急性缺血性卒中患者的心房颤动与再灌注治疗:患病率与结局——一项全面的系统评价和荟萃分析
Neurol Int. 2023 Aug 25;15(3):1014-1043. doi: 10.3390/neurolint15030065.
10
Novel Antithrombotic Agents in Ischemic Cardiovascular Disease: Progress in the Search for the Optimal Treatment.缺血性心血管疾病中的新型抗血栓药物:寻找最佳治疗方法的进展
J Cardiovasc Dev Dis. 2022 Nov 16;9(11):397. doi: 10.3390/jcdd9110397.